Genital herpes - Articles and news items

HerpV and GEN-003 will drive genital herpes treatment market growth to 2023, says GlobalData

Industry news / 21 July 2015 / Victoria White

The global market value for genital herpes therapeutics will increase from around $490 million in 2013 to just under $668 million by 2023, says GlobalData…

Genocea announces positive top-line data from Phase 2 GEN-003 optimisation trial

Industry news / 20 May 2015 / Victoria White

Genocea Biosciences has announced positive top-line data from a Phase 2 dose optimisation trial evaluating GEN-003 for the treatment of genital herpes…

Genocea’s GEN-003 in prime position to lead genital herpes vaccine space, says GlobalData Analyst

Industry news / 30 April 2015 / Victoria White

Genocea’s GEN-003 is better positioned to compete in the future genital herpes treatment space, despite being slightly behind Agenus’ HerpV in development…

Herpes Simplex Virus 1 (HSV-1) capsid

New Genital Herpes vaccine entrants require improved efficacy to compete, says GlobalData analyst

Industry news / 31 October 2014 / GlobalData

While the collaboration between Sanofi Pasteur (Sanofi) and Immune Design to develop a genital herpes vaccine presents a strong scientific foundation and difficult-to-match financial clout, the partnership needs to create a product with better clinical performance to compete with more advanced pipeline vaccine candidates, says an analyst with research and consulting firm GlobalData.

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+